[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital mortality, length of stay total charges, and stroke morbidity among inpatient admissions with a principal diagnosis of ischemic stroke.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of Stroke.\nIschemic Stroke + Atrial Fibrillation Categories:\n\nIschemic Stroke with Atrial Fibrillation\nIschemic Stroke without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nStroke-related morbidity\n\nIntracranial Hemorrhage\nSepsis\n\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, rheumatic valvular disease, chronic obstructive pulmonary disease, dementia, cirrhosis, obstructive sleep apnea, anemia, obesity, prior stroke, prior cardiac surgery, presence of pacemaker/defibrillator, alochol use disorder, tobacco use disorder, use of tissue plasminogen activator and use of thrombectomy.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "",
    "text": "Reference Papers:\n\nSidhu et al. 2022\n\nStudy Objective: Examine the impact of atrial fibrillation on in-hospital mortality, length of stay total charges, and stroke morbidity among inpatient admissions with a principal diagnosis of ischemic stroke.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with a principal diagnosis of Stroke.\nIschemic Stroke + Atrial Fibrillation Categories:\n\nIschemic Stroke with Atrial Fibrillation\nIschemic Stroke without Atrial Fibrillation\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nSecondary Outcomes:\n\nStroke-related morbidity\n\nIntracranial Hemorrhage\nSepsis\n\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of atrial fibrillation with in-hospital mortality, stroke mortality, length of stay and total charges (inflation adjusted), respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance, hospital region, hospital bedsize, hospital location, and teaching status.\nMedical History: Hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, peripheral vascular disease, heart failure, chronic kidney disease, rheumatic valvular disease, chronic obstructive pulmonary disease, dementia, cirrhosis, obstructive sleep apnea, anemia, obesity, prior stroke, prior cardiac surgery, presence of pacemaker/defibrillator, alochol use disorder, tobacco use disorder, use of tissue plasminogen activator and use of thrombectomy.\nComorbidities: Charlson comorbidity index.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 1,616,475\n1\nIschemic Stroke with Atrial Fibrillation\nN = 346,065\n1\nIschemic Stroke without Atrial Fibrillation\nN = 1,270,410\n1\np-value\n2\n\n\n\n\nAge, y\n70 (14)\n77 (11)\n68 (14)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n796,425 (49)\n180,130 (52)\n616,295 (49)\n\n\n\n\n    Male\n819,985 (51)\n165,930 (48)\n654,055 (51)\n\n\n\n\nRace\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n1,068,285 (68)\n256,635 (76)\n811,650 (66)\n\n\n\n\n    Asian or Pacific Islander\n49,070 (3.1)\n10,540 (3.1)\n38,530 (3.1)\n\n\n\n\n    Black\n275,775 (18)\n37,790 (11)\n237,985 (19)\n\n\n\n\n    Hispanic\n133,010 (8.4)\n22,785 (6.8)\n110,225 (8.9)\n\n\n\n\n    Native American\n7,675 (0.5)\n975 (0.3)\n6,700 (0.5)\n\n\n\n\n    Other\n41,525 (2.6)\n8,385 (2.5)\n33,140 (2.7)\n\n\n\n\nCharlson comorbidity index\n3.78 (2.10)\n4.16 (2.18)\n3.68 (2.07)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n487,600 (31)\n91,180 (27)\n396,420 (32)\n\n\n\n\n    $52,000 - $65,999\n425,995 (27)\n91,510 (27)\n334,485 (27)\n\n\n\n\n    $66,000 - $87,999\n376,065 (24)\n84,245 (25)\n291,820 (23)\n\n\n\n\n    $88,000 or more\n301,010 (19)\n74,175 (22)\n226,835 (18)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n382,185 (24)\n46,770 (14)\n335,415 (26)\n\n\n\n\n    Medicaid\n154,420 (9.6)\n15,610 (4.5)\n138,810 (11)\n\n\n\n\n    Medicare\n1,039,315 (64)\n276,965 (80)\n762,350 (60)\n\n\n\n\n    Other\n38,385 (2.4)\n6,440 (1.9)\n31,945 (2.5)\n\n\n\n\nHospital region\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n349,315 (22)\n76,660 (22)\n272,655 (21)\n\n\n\n\n    Northeast\n278,005 (17)\n65,150 (19)\n212,855 (17)\n\n\n\n\n    South\n685,800 (42)\n134,915 (39)\n550,885 (43)\n\n\n\n\n    West\n303,355 (19)\n69,340 (20)\n234,015 (18)\n\n\n\n\nHospital bedsize\n\n\n\n\n\n\n&lt;0.001\n\n\n    Large\n855,655 (53)\n188,105 (54)\n667,550 (53)\n\n\n\n\n    Medium\n465,410 (29)\n98,710 (29)\n366,700 (29)\n\n\n\n\n    Small\n295,410 (18)\n59,250 (17)\n236,160 (19)\n\n\n\n\nHospital location and teaching status\n\n\n\n\n\n\n&lt;0.001\n\n\n    Rural\n115,015 (7.1)\n23,040 (6.7)\n91,975 (7.2)\n\n\n\n\n    Urban, non-teaching\n284,665 (18)\n56,985 (16)\n227,680 (18)\n\n\n\n\n    Urban, teaching\n1,216,795 (75)\n266,040 (77)\n950,755 (75)\n\n\n\n\nHypertension\n1,371,415 (85)\n306,490 (89)\n1,064,925 (84)\n&lt;0.001\n\n\nDiabetes mellitus\n637,165 (39)\n126,115 (36)\n511,050 (40)\n&lt;0.001\n\n\nHyperlipidemia\n984,900 (61)\n213,820 (62)\n771,080 (61)\n&lt;0.001\n\n\nCoronary artery disease\n381,665 (24)\n111,210 (32)\n270,455 (21)\n&lt;0.001\n\n\nPeripheral vascular disease\n149,030 (9.2)\n41,030 (12)\n108,000 (8.5)\n&lt;0.001\n\n\nHeart failure\n309,465 (19)\n115,885 (33)\n193,580 (15)\n&lt;0.001\n\n\nChronic kidney disease\n303,070 (19)\n83,050 (24)\n220,020 (17)\n&lt;0.001\n\n\nRheumatic valvular disease\n48,845 (3.0)\n18,945 (5.5)\n29,900 (2.4)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n261,675 (16)\n64,300 (19)\n197,375 (16)\n&lt;0.001\n\n\nDementia\n178,840 (11)\n54,170 (16)\n124,670 (9.8)\n&lt;0.001\n\n\nCirrhosis\n19,615 (1.2)\n4,835 (1.4)\n14,780 (1.2)\n&lt;0.001\n\n\nObstructive sleep apnea\n112,705 (7.0)\n28,885 (8.3)\n83,820 (6.6)\n&lt;0.001\n\n\nAnemia\n54,145 (3.3)\n13,845 (4.0)\n40,300 (3.2)\n&lt;0.001\n\n\nObesity\n245,670 (15)\n47,940 (14)\n197,730 (16)\n&lt;0.001\n\n\nPrior stroke\n246,410 (15)\n55,960 (16)\n190,450 (15)\n&lt;0.001\n\n\nPrior cardiac surgery\n119,320 (7.4)\n38,695 (11)\n80,625 (6.3)\n&lt;0.001\n\n\nPacemaker/ICD\n71,430 (4.4)\n34,135 (9.9)\n37,295 (2.9)\n&lt;0.001\n\n\nAlcohol use disorder\n493,800 (31)\n113,510 (33)\n380,290 (30)\n&lt;0.001\n\n\nTobbacco use disorder\n14,885 (0.9)\n1,745 (0.5)\n13,140 (1.0)\n&lt;0.001\n\n\nTissue plasminogen activator\n152,670 (9.4)\n33,060 (9.6)\n119,610 (9.4)\n0.29\n\n\nThrombectomy use\n67,690 (4.2)\n26,595 (7.7)\n41,095 (3.2)\n&lt;0.001\n\n\n\n1\nMean (SD); n (%)\n\n\n2\nDesign-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 1,616,475\n1\nIschemic Stroke with Atrial Fibrillation\nN = 346,065\n1\nIschemic Stroke without Atrial Fibrillation\nN = 1,270,410\n1\np-value\n2\n\n\n\n\nDied during hospitalization\n62,560 (3.9)\n22,940 (6.6)\n39,620 (3.1)\n&lt;0.001\n\n\nLength of stay (days)\n5.1 (6.8)\n5.7 (7.0)\n4.9 (6.8)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n72,547 (97,730)\n82,654 (108,618)\n69,797 (94,364)\n&lt;0.001\n\n\nStroke-related morbidity\n106,880 (6.6)\n34,750 (10)\n72,130 (5.7)\n&lt;0.001\n\n\nIntracranial Hemorrhage\n95,055 (5.9)\n31,330 (9.1)\n63,725 (5.0)\n&lt;0.001\n\n\nSepsis\n14,340 (0.9)\n4,170 (1.2)\n10,170 (0.8)\n&lt;0.001\n\n\n\n1\nn (%); Mean (SD)\n\n\n2\nPearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.66 (0.63 to 0.68)\n&lt;0.001\n\n\nAge, y\n1.04 (1.03 to 1.04)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.01 (0.97 to 1.05)\n0.75\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.07 (0.96 to 1.19)\n0.20\n\n\n    Black\n0.81 (0.76 to 0.87)\n&lt;0.001\n\n\n    Hispanic\n0.88 (0.81 to 0.96)\n0.003\n\n\n    Native American\n0.95 (0.72 to 1.27)\n0.75\n\n\n    Other\n1.15 (1.02 to 1.29)\n0.024\n\n\nCharlson comorbidity index\n1.18 (1.16 to 1.19)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.93 (0.89 to 0.98)\n0.011\n\n\n    $66,000 - $87,999\n0.86 (0.81 to 0.91)\n&lt;0.001\n\n\n    $88,000 or more\n0.82 (0.77 to 0.87)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n1.05 (0.96 to 1.15)\n0.26\n\n\n    Medicare\n0.79 (0.74 to 0.85)\n&lt;0.001\n\n\n    Other\n1.68 (1.45 to 1.94)\n&lt;0.001\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n1.12 (1.03 to 1.22)\n0.006\n\n\n    South\n1.00 (0.94 to 1.07)\n0.97\n\n\n    West\n1.17 (1.09 to 1.26)\n&lt;0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.82 (0.77 to 0.87)\n&lt;0.001\n\n\n    Small\n0.65 (0.61 to 0.70)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n0.88 (0.79 to 0.97)\n0.011\n\n\n    Urban, teaching\n1.24 (1.13 to 1.35)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.63 (0.60 to 0.66)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.86 (0.82 to 0.90)\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.54 (0.52 to 0.57)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.00 (0.95 to 1.05)\n0.92\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.83 to 0.95)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.46 (1.39 to 1.53)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.80 (0.75 to 0.84)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.84 to 0.94)\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.85 (0.80 to 0.90)\n&lt;0.001\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.67 (2.38 to 2.98)\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.75 (0.68 to 0.82)\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.73 (0.66 to 0.82)\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.93 to 1.04)\n0.55\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.80 (0.75 to 0.86)\n&lt;0.001\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.71 (0.63 to 0.79)\n&lt;0.001\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.75 (0.71 to 0.80)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.85 (0.79 to 0.92)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.82 to 0.97)\n0.011\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.68 (0.52 to 0.90)\n0.006\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.92 to 1.04)\n0.49\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.45 (2.29 to 2.63)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nStroke-Related Morbidity (ICH and Sepsis):\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.64 (0.62 to 0.66)\n&lt;0.001\n\n\nAge, y\n1.00 (1.00 to 1.00)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.15 (1.11 to 1.18)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.40 (1.29 to 1.51)\n&lt;0.001\n\n\n    Black\n0.94 (0.90 to 0.99)\n0.015\n\n\n    Hispanic\n1.19 (1.12 to 1.26)\n&lt;0.001\n\n\n    Native American\n0.83 (0.65 to 1.06)\n0.14\n\n\n    Other\n1.31 (1.20 to 1.43)\n&lt;0.001\n\n\nCharlson comorbidity index\n1.10 (1.09 to 1.11)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.95 (0.91 to 0.99)\n0.014\n\n\n    $66,000 - $87,999\n0.95 (0.91 to 0.99)\n0.019\n\n\n    $88,000 or more\n0.96 (0.92 to 1.01)\n0.13\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n1.20 (1.13 to 1.27)\n&lt;0.001\n\n\n    Medicare\n1.14 (1.09 to 1.19)\n&lt;0.001\n\n\n    Other\n1.14 (1.03 to 1.26)\n0.013\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n1.21 (1.13 to 1.29)\n&lt;0.001\n\n\n    South\n1.04 (0.98 to 1.10)\n0.22\n\n\n    West\n1.02 (0.96 to 1.09)\n0.45\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.72 (0.69 to 0.76)\n&lt;0.001\n\n\n    Small\n0.54 (0.51 to 0.57)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n1.70 (1.49 to 1.94)\n&lt;0.001\n\n\n    Urban, teaching\n2.83 (2.51 to 3.19)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.79 (0.76 to 0.83)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.97 (0.93 to 1.00)\n0.060\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.77 (0.75 to 0.80)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.96 (0.92 to 1.00)\n0.034\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.88 (0.83 to 0.93)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.38 (1.32 to 1.43)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.75 (0.72 to 0.79)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.79 to 0.85)\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.90 (0.86 to 0.95)\n&lt;0.001\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.78 (1.61 to 1.97)\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.94 (0.88 to 1.00)\n0.042\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.90 to 1.06)\n0.59\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.11 (1.06 to 1.16)\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.90 (0.86 to 0.94)\n&lt;0.001\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.96 (0.88 to 1.05)\n0.36\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.79 (0.75 to 0.82)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.83 to 0.95)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.67 (0.62 to 0.72)\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.75 (0.63 to 0.90)\n0.002\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.58 (1.52 to 1.65)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n3.95 (3.76 to 4.15)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nIntracranial Hemorrhage:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.63 (0.61 to 0.65)\n&lt;0.001\n\n\nAge, y\n1.00 (1.00 to 1.00)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.13 (1.10 to 1.17)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.39 (1.28 to 1.51)\n&lt;0.001\n\n\n    Black\n0.94 (0.90 to 0.99)\n0.021\n\n\n    Hispanic\n1.21 (1.14 to 1.29)\n&lt;0.001\n\n\n    Native American\n0.83 (0.64 to 1.08)\n0.16\n\n\n    Other\n1.29 (1.18 to 1.41)\n&lt;0.001\n\n\nCharlson comorbidity index\n1.09 (1.08 to 1.10)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.98 (0.94 to 1.03)\n0.43\n\n\n    $66,000 - $87,999\n0.97 (0.93 to 1.02)\n0.28\n\n\n    $88,000 or more\n0.99 (0.94 to 1.05)\n0.78\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n1.13 (1.06 to 1.21)\n&lt;0.001\n\n\n    Medicare\n1.09 (1.04 to 1.14)\n&lt;0.001\n\n\n    Other\n1.06 (0.95 to 1.18)\n0.28\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n1.22 (1.13 to 1.31)\n&lt;0.001\n\n\n    South\n1.00 (0.94 to 1.06)\n0.88\n\n\n    West\n1.00 (0.93 to 1.07)\n0.99\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.72 (0.68 to 0.76)\n&lt;0.001\n\n\n    Small\n0.52 (0.49 to 0.55)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n1.65 (1.43 to 1.91)\n&lt;0.001\n\n\n    Urban, teaching\n2.83 (2.48 to 3.23)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.88 (0.84 to 0.92)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.96 (0.93 to 1.00)\n0.055\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.79 to 0.85)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.94 to 1.02)\n0.25\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.87 (0.83 to 0.93)\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.28 (1.23 to 1.34)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.72 (0.69 to 0.76)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.81 (0.77 to 0.85)\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.84 to 0.94)\n&lt;0.001\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.15 (1.02 to 1.30)\n0.021\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.92 to 1.04)\n0.50\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.92 (0.84 to 1.00)\n0.046\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.09 (1.04 to 1.14)\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.90 (0.86 to 0.95)\n&lt;0.001\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.95 (0.87 to 1.04)\n0.26\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.83 (0.79 to 0.87)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.89 (0.83 to 0.95)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.72 (0.66 to 0.78)\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.81 (0.67 to 0.97)\n0.026\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.69 (1.61 to 1.77)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.21 (4.00 to 4.42)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nSepsis:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n0.76 (0.69 to 0.84)\n&lt;0.001\n\n\nAge, y\n1.00 (0.99 to 1.00)\n0.089\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n1.28 (1.18 to 1.39)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n1.42 (1.16 to 1.75)\n&lt;0.001\n\n\n    Black\n0.95 (0.85 to 1.06)\n0.39\n\n\n    Hispanic\n1.09 (0.95 to 1.25)\n0.21\n\n\n    Native American\n0.92 (0.52 to 1.61)\n0.76\n\n\n    Other\n1.46 (1.19 to 1.77)\n&lt;0.001\n\n\nCharlson comorbidity index\n1.13 (1.11 to 1.15)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n0.78 (0.70 to 0.86)\n&lt;0.001\n\n\n    $66,000 - $87,999\n0.82 (0.74 to 0.92)\n&lt;0.001\n\n\n    $88,000 or more\n0.80 (0.71 to 0.90)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n1.69 (1.47 to 1.95)\n&lt;0.001\n\n\n    Medicare\n1.49 (1.32 to 1.70)\n&lt;0.001\n\n\n    Other\n1.63 (1.29 to 2.07)\n&lt;0.001\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n1.07 (0.92 to 1.23)\n0.40\n\n\n    South\n1.33 (1.19 to 1.50)\n&lt;0.001\n\n\n    West\n1.18 (1.03 to 1.36)\n0.017\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n0.77 (0.69 to 0.85)\n&lt;0.001\n\n\n    Small\n0.68 (0.60 to 0.77)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n2.11 (1.64 to 2.71)\n&lt;0.001\n\n\n    Urban, teaching\n2.88 (2.28 to 3.63)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.43 (0.39 to 0.47)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.98 (0.90 to 1.08)\n0.71\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.51 (0.47 to 0.55)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.87 (0.78 to 0.97)\n0.009\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.94 (0.82 to 1.09)\n0.42\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.26 (2.06 to 2.49)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.05 (0.94 to 1.17)\n0.40\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.92 (0.83 to 1.02)\n0.12\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.93 (0.81 to 1.05)\n0.25\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n4.83 (4.14 to 5.64)\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.61 (0.50 to 0.75)\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.25 (1.05 to 1.48)\n0.010\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.20 (1.10 to 1.32)\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.91 (0.81 to 1.02)\n0.11\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.07 (0.86 to 1.32)\n0.55\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.50 (0.43 to 0.58)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.81 (0.67 to 0.98)\n0.028\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.37 (0.28 to 0.48)\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.43 (0.24 to 0.78)\n0.006\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.81 (0.71 to 0.93)\n0.003\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.79 (1.56 to 2.05)\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Clinical Outcomes of Atrial Fibrillation in Acute Ischemic Stroke Patients",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n-0.59 (-0.65 to -0.52)\n&lt;0.001\n\n\nAge, y\n0.00 (-0.01 to 0.00)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n0.24 (0.19 to 0.29)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n0.61 (0.45 to 0.77)\n&lt;0.001\n\n\n    Black\n0.92 (0.83 to 1.0)\n&lt;0.001\n\n\n    Hispanic\n0.48 (0.37 to 0.59)\n&lt;0.001\n\n\n    Native American\n0.08 (-0.26 to 0.42)\n0.65\n\n\n    Other\n0.83 (0.63 to 1.0)\n&lt;0.001\n\n\nCharlson comorbidity index\n0.39 (0.37 to 0.41)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n-0.18 (-0.25 to -0.11)\n&lt;0.001\n\n\n    $66,000 - $87,999\n-0.23 (-0.30 to -0.15)\n&lt;0.001\n\n\n    $88,000 or more\n-0.30 (-0.39 to -0.21)\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n2.0 (1.8 to 2.1)\n&lt;0.001\n\n\n    Medicare\n0.16 (0.09 to 0.23)\n&lt;0.001\n\n\n    Other\n0.39 (0.19 to 0.59)\n&lt;0.001\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n0.63 (0.50 to 0.75)\n&lt;0.001\n\n\n    South\n0.51 (0.42 to 0.60)\n&lt;0.001\n\n\n    West\n-0.08 (-0.19 to 0.03)\n0.14\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n-0.62 (-0.71 to -0.53)\n&lt;0.001\n\n\n    Small\n-1.1 (-1.2 to -0.97)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n0.32 (0.20 to 0.44)\n&lt;0.001\n\n\n    Urban, teaching\n1.1 (1.0 to 1.2)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.30 (-0.39 to -0.21)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.17 (-0.23 to -0.11)\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.58 (-0.64 to -0.53)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.13 (-0.19 to -0.07)\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.10 (-0.19 to -0.02)\n0.020\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.0 (0.91 to 1.1)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.44 (-0.52 to -0.36)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.30 (-0.36 to -0.23)\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.82 (0.73 to 0.92)\n&lt;0.001\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.4 (1.0 to 1.7)\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.16 (-0.24 to -0.07)\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1.4 (1.3 to 1.6)\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.25 (0.16 to 0.33)\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.02 (-0.05 to 0.09)\n0.61\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n0.31 (0.17 to 0.45)\n&lt;0.001\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.62 (-0.68 to -0.56)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.42 (-0.50 to -0.34)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.82 (-0.91 to -0.73)\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.20 (-0.43 to 0.03)\n0.092\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-0.16 (-0.24 to -0.08)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2.4 (2.2 to 2.6)\n&lt;0.001\n\n\n\n1\nCI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta (95% CI)\n1\np-value\n\n\n\n\nAtrial fibrillation categories\n\n\n\n\n\n\n    Ischemic Stroke with Atrial Fibrillation\n—\n\n\n\n\n    Ischemic Stroke without Atrial Fibrillation\n-9,021 (-10,001 to -8,042)\n&lt;0.001\n\n\nAge, y\n-380 (-423 to -336)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n    Female\n—\n\n\n\n\n    Male\n3,512 (2,837 to 4,186)\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n    White\n—\n\n\n\n\n    Asian or Pacific Islander\n12,295 (8,357 to 16,232)\n&lt;0.001\n\n\n    Black\n7,517 (5,712 to 9,323)\n&lt;0.001\n\n\n    Hispanic\n20,399 (17,391 to 23,407)\n&lt;0.001\n\n\n    Native American\n-11,859 (-15,810 to -7,907)\n&lt;0.001\n\n\n    Other\n23,052 (19,122 to 26,983)\n&lt;0.001\n\n\nCharlson comorbidity index\n4,350 (4,063 to 4,636)\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n    $1 - $51,999\n—\n\n\n\n\n    $52,000 - $65,999\n-1,261 (-2,610 to 89)\n0.067\n\n\n    $66,000 - $87,999\n-1,518 (-3,200 to 165)\n0.077\n\n\n    $88,000 or more\n1,766 (-704 to 4,236)\n0.16\n\n\nExpected primary payer\n\n\n\n\n\n\n    Private\n—\n\n\n\n\n    Medicaid\n13,191 (11,238 to 15,144)\n&lt;0.001\n\n\n    Medicare\n3,979 (2,906 to 5,052)\n&lt;0.001\n\n\n    Other\n1,547 (-1,237 to 4,331)\n0.28\n\n\nHospital region\n\n\n\n\n\n\n    Midwest\n—\n\n\n\n\n    Northeast\n21,009 (17,184 to 24,833)\n&lt;0.001\n\n\n    South\n13,201 (11,058 to 15,345)\n&lt;0.001\n\n\n    West\n31,025 (27,645 to 34,405)\n&lt;0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n    Large\n—\n\n\n\n\n    Medium\n-7,647 (-10,285 to -5,009)\n&lt;0.001\n\n\n    Small\n-15,249 (-18,043 to -12,455)\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n    Rural\n—\n\n\n\n\n    Urban, non-teaching\n23,063 (20,596 to 25,529)\n&lt;0.001\n\n\n    Urban, teaching\n30,646 (28,931 to 32,362)\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-5,266 (-6,654 to -3,877)\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-2,470 (-3,371 to -1,569)\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-5,780 (-6,641 to -4,919)\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n751 (-119 to 1,622)\n0.091\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n615 (-719 to 1,949)\n0.37\n\n\nHeart failure\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n10,936 (9,774 to 12,099)\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-7,577 (-8,753 to -6,401)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-2,112 (-3,089 to -1,136)\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-2,038 (-3,049 to -1,027)\n&lt;0.001\n\n\nCirrhosis\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n32,551 (25,847 to 39,255)\n&lt;0.001\n\n\nObstructive sleep apnea\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-4,483 (-5,760 to -3,207)\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n15,573 (13,274 to 17,872)\n&lt;0.001\n\n\nAlcohol use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n5,959 (3,252 to 8,666)\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n2,178 (1,023 to 3,334)\n&lt;0.001\n\n\nRheumatic valvular disease\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n1,489 (-589 to 3,568)\n0.16\n\n\nPrior stroke\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-5,831 (-6,813 to -4,850)\n&lt;0.001\n\n\nPrior cardiac surgery\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-5,394 (-6,565 to -4,224)\n&lt;0.001\n\n\nPacemaker/ICD\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-11,882 (-13,240 to -10,524)\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n-3,219 (-6,410 to -29)\n0.048\n\n\nTissue plasminogen activator\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n44,658 (42,895 to 46,421)\n&lt;0.001\n\n\nThrombectomy use\n\n\n\n\n\n\n    No\n—\n\n\n\n\n    Yes\n113,224 (108,066 to 118,383)\n&lt;0.001\n\n\n\n1\nCI = Confidence Interval"
  }
]